Dec 01, 2025
Zymeworks Stock Skyrockets After Cancer Breakthrough — But What’s Next?
Zymeworks soared 34% after its partnered drug Ziihera posted strong Phase 3 data, with Jazz Pharmaceuticals showing it improved outcomes in a tough cancer — a breakthrough moment for the company.
8 min read8' read
Hot Animals Videos 🐟
SUPPER CHANGE YOUR PLANNING POWERS
Join our newsletter 🎉
Read and share new perspectives on just about any topic. Everyone’s welcome.- 01Create a free account
- 02Write your story

More Hot Videos 🏑
s



















